TLDR
- Petrelintide, Zealand Pharma’s obesity candidate, achieved 10.7% weight reduction at 42 weeks in Phase 2 testing — falling short of the 12–15% analyst consensus
- Wall Street firms including JPMorgan, Jefferies, UBS, and Barclays characterized the findings as underwhelming
- Cantor Fitzgerald lowered its rating from Overweight to Neutral on the stock
- Competing programs from Eli Lilly (eloralintide) and Novo Nordisk (cagrilintide) appear to have superior efficacy profiles
- Absence of dose-dependent response between highest dose cohorts casts doubt on Phase 3 improvement potential
Shares of Zealand Pharma (ZEAL) plummeted over 32% Friday following the release of Phase 2 clinical data for petrelintide, its obesity treatment candidate, which underperformed Wall Street forecasts.
The ZUPREME-1 study, conducted in collaboration with Roche, evaluated petrelintide in overweight and obese individuals who did not have type 2 diabetes. Participants receiving the maximum dose achieved an average body weight reduction of 10.7% by week 42 using an efficacy estimand analysis.
While the study successfully achieved its primary endpoint by demonstrating statistically significant weight reductions at 28 weeks across all dosing cohorts compared to placebo, the topline figure failed to satisfy market expectations.
Wall Street analysts had been projecting weight loss in the 12% to 15% range to establish meaningful competitive positioning. The actual 10.7% outcome fell considerably below that threshold.
JPMorgan analyst Sophia Graeff Buhl Nielsen characterized the outcome as “falls slightly short of expectations,” while noting the data “leaves scope for an attractive mid-teens weight loss profile to be achieved in Phase 3,” particularly if future enrollment includes more female subjects — a subgroup that demonstrated superior response rates.
Jefferies warned the data would likely disappoint, coming in below both its internal projection of 13% to 15% and buy-side expectations exceeding 15%. Analyst Lucy Codrington characterized petrelintide as having “Wegovy-like efficacy, but with placebo-like tolerability,” calling it “viable” though probably “2nd-best to LLY’s elora for now.”
The drug did excel in one important dimension: safety and tolerability. The highest-dose cohort reported zero vomiting incidents and minimal gastrointestinal adverse events — what Codrington described as a “placebo-like” safety profile. While this represents a genuine advantage, it wasn’t sufficient to offset efficacy concerns.
Cantor Fitzgerald Downgrades to Neutral
Cantor Fitzgerald downgraded Zealand Pharma from Overweight to Neutral, citing insufficient differentiation from competitors. The investment bank noted that petrelintide’s placebo-adjusted weight reduction of approximately 9% at week 42 mirrors Novo Nordisk’s cagrilintide results — and trails meaningfully behind Eli Lilly’s eloralintide.
Cantor expressed concern about the absence of a clear dose-response relationship, suggesting limited evidence that weight loss outcomes will improve in subsequent trials. The firm now projects petrelintide will achieve weight reduction in the low-teens percentage range, comparable to cagrilintide.
With Eli Lilly already advancing eloralintide into Phase 3 and Novo Nordisk progressing cagrilintide monotherapy through Phase 3 development, Cantor suggested petrelintide could enter the market as a third entrant with limited competitive differentiation. That positioning presents significant commercial challenges.
What’s Left to Watch
UBS observed that the trial results landed “clearly at the lower end of expectations” and questioned petrelintide’s viability as a standalone monotherapy. Nevertheless, the bank highlighted a combination strategy — pairing petrelintide with a low dose of Roche’s CT-388 — as a “still viable option,” particularly given the favorable tolerability data.
The top dose groups showed minimal separation, with weight loss outcomes ranging only between 10.2% and 10.7%. JPMorgan suggested this narrow range may indicate limited incremental benefit from dose escalation.
Comprehensive trial data is scheduled for presentation at a scientific conference in 2026.
ZEAL shares were trading at $38.22 at last check, representing approximately 51% below the 52-week peak of $112.63.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
